

UCLA

UCLA Previously Published Works

Title

Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061

Permalink

<https://escholarship.org/uc/item/7w26n99f>

Journal

Gastric Cancer, 24(6)

ISSN

1436-3291

Authors

Van Cutsem, Eric
Amonkar, Mayur
Fuchs, Charles S
[et al.](#)

Publication Date

2021-11-01


DOI

10.1007/s10120-021-01200-w

Peer reviewed



Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061

Eric Van Cutsem¹ · Mayur Amonkar² · Charles S. Fuchs³ · Maria Alsina⁴ · Mustafa Özgüroğlu⁵ · Yung-Jue Bang⁶ · Hyun Cheol Chung⁷ · Kei Muro⁸ · Eray Goekkurt⁹ · Al B. Benson III¹⁰ · Weijing Sun¹¹ · Zev A. Wainberg¹² · Josephine M. Norquist² · Xinqun Chen¹³ · Chie-Schin Shih¹³ · Kohei Shitara¹⁴ 

Received: 9 November 2020 / Accepted: 18 May 2021 / Published online: 7 August 2021
© The Author(s) 2021, corrected publication 2021

Abstract

Background In the primary analysis population (i.e., PD-L1 combined positive score [CPS] ≥ 1) of the phase 3 KEYNOTE-061 study (NCT02370498), pembrolizumab did not significantly prolong overall survival or progression-free survival. Pembrolizumab had a favorable safety profile in the all-patient population. We present results of prespecified health-related quality of life (HRQoL) analyses.

Methods HRQoL was measured using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), EORTC QLQ gastric cancer questionnaire (QLQ-STO22), and EuroQol 5-dimension, 3-level questionnaire (EQ-5D-3L). Data were analyzed from patients who received ≥ 1 dose of study treatment and who completed ≥ 1 HRQoL assessment. Key analyses included baseline to week 12 least-squares mean (LSM) change in global health status (GHS)/QoL, functional/symptom subscales, and time to deterioration (TTD; ≥ 10 -point decrease from baseline) for specific subscales.

Results The HRQoL population included 371 patients (pembrolizumab, $n = 188$; paclitaxel, $n = 183$). Compliance and completion rates for all 3 questionnaires were similar in both groups at baseline and week 12. There was no difference in LSM change between groups (-3.54 ; 95% CI -8.92 to 1.84) in GHS/QoL at week 12. LSM change from baseline to week 12 for most QLQ-C30, QLQ-STO22, and EQ-5D-3L subscales indicated some worsening of QoL in both groups. TTD for GHS/QoL, nausea/vomiting, and appetite loss subscales in QLQ-C30 and the pain subscales in QLQ-STO22 were similar between treatment groups.

Conclusions In this population with advanced gastric and GEJ cancer receiving second-line treatment, HRQoL was similar in patients receiving pembrolizumab and those receiving paclitaxel.

Clinical trial registry and number ClinicalTrials.gov, NCT02370498.

Keywords Pembrolizumab · Chemotherapy · Gastric cancer · HRQoL

Introduction

Gastric cancer is the fifth most common cancer worldwide; in 2018 alone, more than 1 million new cases were diagnosed globally and nearly 800,000 deaths occurred [1].

Patients with advanced-stage gastric and/or gastroesophageal junction (GEJ) cancer experience diminished health-related quality of life (HRQoL)—overall health status and functioning decrease while the burden of cancer-related symptoms increases [2, 3]. The type of symptom burden also changes; weight loss, abdominal pain, vomiting, gastric obstruction, and gastric bleeding are more commonly associated with advanced-stage gastric/GEJ [2]. In addition to disease-related symptoms, those related to chemotherapy in patients with advanced gastric/GEJ cancer include abdominal pain, fatigue, nausea/vomiting, and diarrhea [2]. Treatments for gastric/GEJ cancer should, therefore, be evaluated for their effects on patients' already diminished HRQoL associated with the disease.

Previously presented as an abstract and a poster at the European Society of Medical Oncology annual meeting on September 29, 2019

The original online version of this article was revised to add missing information in declarations section.

✉ Eric Van Cutsem
eric.vancutsem@uzleuven.be

Extended author information available on the last page of the article

The current recommended systemic treatment options for gastric/GEJ cancer include first-line treatment with platinum plus fluoropyrimidine (in combination with trastuzumab in HER2-positive tumors) and second-line or subsequent treatment with docetaxel, paclitaxel, irinotecan, fluorouracil and irinotecan, or paclitaxel and ramucirumab or with pembrolizumab in patients with high microsatellite instability or mismatch protein repair-deficient tumors [4]. Regimens preferred in the third-line or later setting include trifluridine plus tipiracil and pembrolizumab as described below [4]. Modest improvements in HRQoL were observed for a minority of treatment regimens in the first-line setting—single-agent chemotherapy led to clinically significant improvement in overall, function, and symptom scores over approximately 4 months. In the second-line or later setting, overall HRQoL remained stable for nearly all treatments, whereas role functioning, fatigue, appetite loss, and distress from hair loss scores worsened over time [5].

Pembrolizumab, an anti-programmed death 1 (PD-1) monoclonal antibody, has demonstrated antitumor activity, greater durability of response, and manageable safety in patients with advanced gastric/GEJ cancer [6, 7]. Pembrolizumab is approved by the US Food and Drug Administration as third-line or later therapy for gastric/GEJ cancer that is PD-1 ligand 1 (PD-L1)-positive (combined positive score [CPS] ≥ 1) [8]. In KEYNOTE-061 (NCT02370498), pembrolizumab did not prolong overall survival (OS) or progression-free survival as second-line therapy for advanced gastric/GEJ cancer in the primary analysis population (PD-L1 CPS ≥ 1); however, the antitumor activity of pembrolizumab (objective response rate [ORR], 16%) was more durable (median duration of response [DOR], 18.0 months) than paclitaxel (ORR, 14%; median DOR, 5.2 months) [9]. Pembrolizumab also had a better safety profile than paclitaxel. We report the results of prespecified exploratory end points for HRQoL from KEYNOTE-061.

Methods

Study design and patients

The methods and primary results of the KEYNOTE-061 study have been described in detail elsewhere [9]. Brief details are provided in the Online Resource Methods.

The study protocol and all amendments were approved by the institutional review board or ethics committee at each institution. The study was conducted in accordance with the protocol and its amendments and with Good Clinical Practice guidelines. All patients provided written informed consent before enrollment.

HRQoL outcomes

The prespecified HRQoL-based exploratory objectives were to evaluate mean score changes from baseline to week 12 in HRQoL using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) [10–13] and the EORTC QLQ gastric cancer questionnaire (QLQ-STO22) [14, 15] from baseline to week 12 and to characterize utilities using the EuroQol 5-dimension, 3-level questionnaire (EQ-5D-3L) [16, 17] among patients treated with pembrolizumab versus paclitaxel.

Other measures included completion and compliance with EORTC QLQ-C30, EORTC QLQ-STO22, and the EQ-5D-3L; mean score change from baseline to week 12 in the EORTC QLQ-C30 global health status/quality of life (GHS/QoL) scale; mean score change from baseline to week 12 for subscales and items with EORTC QLQ-C30 (5 functional dimensions: physical, role, emotional, cognitive, and social; 3 symptom scales: fatigue, nausea/vomiting, and pain; 6 single-item measures: dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and EORTC QLQ-STO22 (22 items; 5-multi-items scales [dysphagia, pain, reflux symptoms eating restrictions anxiety] and 4 single items [dry mouth, taste, body image, and hair loss]; mean score change from baseline to week 12 for EQ-5D-3L visual analog scale (VAS) and utility score; and time to deterioration (TTD) in the GHS/QoL score from baseline with EORTC QLQ-C30 and EORTC QLQ-STO22. Changes in the EORTC QLQ-C30 and EORTC QLQ-STO22 subscales and items were defined as follows: improved, ≥ 10 -point increase; remained stable, no change, or change of < 10 points; deteriorated, ≤ 10 -point decrease.

The HRQoL questionnaires were administered electronically by trained personnel and were completed by patients in the following order: EQ-5D-3L, EORTC QLQ-C30, and EORTC QLQ-STO22. Each questionnaire was administered at baseline and at cycles 1, 2, 3, 4, 5, 7, and 9; every 6 weeks after week 24 through 1 year or end of treatment; and at the 30-day posttreatment discontinuation follow-up visit. Study sites were instructed to make every effort to ensure that administration of HRQoL questionnaires occurred before all other study procedures.

Statistical analysis

In this exploratory analysis with no formal hypothesis testing, data were analyzed for all patients in the primary analysis population who received ≥ 1 dose of study treatment and who completed ≥ 1 HRQoL questionnaire. Compliance

and completion were summarized by treatment group and visit. Compliance was defined by the proportion of patients who completed ≥ 1 HRQoL assessment among those expected to complete the questionnaires at each visit (excluding patients missing by design because they discontinued study treatment). Completion was defined by the proportion of patients who completed ≥ 1 HRQoL assessment among the total HRQoL analysis population at each visit. The protocol-specified primary HRQoL end point was least-squares mean (LSM) change from baseline to week 12, which was assessed using a constrained longitudinal data analysis model, with HRQoL score as the response variable and treatment-by-time interaction and trial stratification factors as covariates.

Multiple imputations based on the missing-at-random assumption were used in the analysis of improved, stable, and deteriorated results from baseline to week 12. TTD in EORTC QLQ-C30 GHS/QoL score was estimated using the Kaplan–Meier method; the hazard ratio was estimated with a stratified (by geographic region and time to progression on first-line therapy) Cox proportional hazards model.

Results

Patients

The primary study population comprised 395 patients with CPS ≥ 1 (pembrolizumab, $n = 196$; paclitaxel, $n = 199$) [9]. At data cutoff (October 26, 2017), 2 patients in the

pembrolizumab group and 11 in the paclitaxel group had not received study medication and 6 and 5 patients, respectively, had not completed an HRQoL questionnaire. The HRQoL analysis population therefore included 188 patients in the pembrolizumab group and 183 patients in the paclitaxel group.

HRQoL compliance and completion

EORTC QLQ-C30 compliance rates were 92.0% and 92.9%, respectively, at baseline in the pembrolizumab group and the paclitaxel group and remained high (86.6% and 82.1%, respectively) for patients on study at week 12 (Table 1). Completion rates decreased over time, and 51.6% of patients in the pembrolizumab group and 55.2% of patients in the paclitaxel group completed the questionnaire at week 12. At week 12, patients in the pembrolizumab group discontinued because of disease progression (31.4%), patient/physician decision (2.2%), adverse event (AE; 1.1%), or death (1.1%) and patients in the paclitaxel group discontinued because of disease progression (22.4%), patient/physician decision (3.3%), AE (4.9%), or death (0.5%). EORTC QLQ-STO22 and EQ-5D-3L compliance and completion rates were similar to those observed for the EORTC QLQ-C30 (Online Resource Tables 1 and 2).

Table 1 Rates of compliance and completion of the EORTC QLQ-C30

Treatment Visit	Compliance ^a		Completion ^b	
	Pembrolizumab <i>n/N</i> (%)	Paclitaxel <i>n/N</i> (%)	Pembrolizumab <i>n/N</i> (%)	Paclitaxel <i>n/N</i> (%)
Baseline	173/188 (92.0)	170/183 (92.9)	173/188 (92.0)	170/183 (92.9)
Week 3 or 4	161/178 (90.4)	127/179 (70.9)	161/188 (85.6)	127/183 (69.4)
Week 6	134/159 (84.3)	117/162 (72.2)	134/188 (71.3)	117/183 (63.9)
Week 9	113/132 (85.6)	107/140 (76.4)	113/188 (60.1)	107/183 (58.5)
Week 12	97/112 (86.6)	101/123 (82.1)	97/188 (51.6)	101/183 (55.2)
Week 18	77/91 (84.6)	70/95 (73.7)	77/188 (41.0)	70/183 (38.3)
Week 24	50/69 (73.5)	42/62 (67.7)	50/188 (26.6)	42/183 (23.0)
Week 30	44/60 (73.3)	18/32 (56.3)	44/188 (23.4)	18/183 (9.8)
Week 36	35/48 (72.9)	12/20 (60.0)	35/188 (18.6)	12/183 (6.6)
Week 42	27/39 (69.2)	11/17 (64.7)	27/188 (14.4)	11/183 (6.0)
Week 48	27/36 (75.0)	7/9 (77.8)	27/188 (14.4)	7/183 (3.8)

EORTC European Organisation for Research and Treatment of Cancer, QLQ-C30 Quality of Life Questionnaire Core 30

^aThe proportion of patients who completed ≥ 1 HRQoL assessment among those expected to complete the instruments at each visit, excluding those missing by design

^bThe proportion of patients who completed ≥ 1 HRQoL assessment among the total HRQoL analysis population at each visit

Table 2 Change from baseline to week 12 in EORTC QLQ-C30 GHS/QoL scores

Results	Pembrolizumab <i>n</i> = 188	Paclitaxel <i>n</i> = 183
Baseline		
<i>n</i>	173	171
Mean (SD)	63.05 (21.326)	62.57 (20.953)
Week 12		
<i>n</i> ^a	98	106
Mean (SD)	63.27 (22.918)	63.68 (20.483)
Change from baseline to week 12, LSM (95% CI)	-6.84 (-10.87 to -2.81)	-3.30 (-7.22 to 0.61)
Difference in LSM (95% CI)	-3.54 (-8.92 to 1.84)	
<i>p</i> value	0.196	

EORTC European Organisation for Research and Treatment of Cancer, LSM least-squares mean, QLQ-C30 Quality of Life Questionnaire Core 30, SD standard deviation

^aNumber of patients in each treatment group with nonmissing assessments at this time point

Change from baseline in HRQoL

EORTC QLQ-C30

Baseline GHS/QoL mean scores were similar between treatment groups (pembrolizumab, 63.05 [SD, 21.326]; paclitaxel, 62.57 [SD, 20.953]) (Table 2). GHS/QoL mean scores worsened slightly from baseline to week 12 in both treatment groups (LSM change: -6.84 for pembrolizumab [95% CI -10.87 to -2.81], -3.30 for paclitaxel [95% CI -7.22 to 0.61]) (Fig. 1). The LSM score change from baseline to week 12 in GHS/QoL score was slightly worse in the pembrolizumab group versus the paclitaxel group (difference, -3.54; 95% CI -8.92 to 1.84; nominal $p=0.196$). At week 12, LSM score changes from baseline indicated worsening of all EORTC QLQ-C30 functional subscale and of most symptom subscale scores in both treatment groups (Fig. 2a,

b). Worsening in these domains was similar in magnitude between pembrolizumab and paclitaxel (Fig. 2a, b). Beginning at week 18, GHS/QoL mean scores showed improvement for patients receiving pembrolizumab (Fig. 1). This trend was not observed in the paclitaxel group; however, comparison of GHS/QoL mean scores for patients receiving paclitaxel is limited because of low completion rates beginning at week 24.

EORTC QLQ-STO22

LSM score changes from baseline to week 12 showed worsening of most EORTC QLQ-STO22 symptom subscales for both treatment groups (Fig. 2c); only mean score changes for anxiety showed improvement in both groups. Mean score change for hair loss was nominally different between treatment groups; patients receiving paclitaxel experienced hair loss, whereas




Fig. 1 Mean (SE) EORTC QLQ-C30 GHS/QoL scores over time. EORTC European Organisation for Research and Treatment of Cancer, GHS global health status, Q3W every 3 weeks, QLQ-30 Quality of Life Questionnaire Core 30, QoL quality of life, SE standard error




Fig. 2 LSM (95% CI) change from baseline to week 12 in **a** EORTC QLQ-C30 GHS/QoL and functional subscale scores, **b** EORTC QLQ-C30 symptom subscale scores, and **c** EORTC QLQ-STO22 symptom subscale scores. *EORTC* European Organisation for Research and

Treatment of Cancer, *GHS* global health status, *LSM* least-squares mean, *Q3W* every 3 weeks, *QLQ-30* Quality of Life Questionnaire Core 30, *QLQ-STO22* health-related QoL questionnaire in gastric cancer, *QoL* quality of life

those receiving pembrolizumab did not. Mean score changes for dysphasia and eating restrictions were worse from baseline to week 12 for patients in the pembrolizumab group, but the difference was minimal compared with scores for patients in the paclitaxel group.

EQ-5D-3L

At week 12, LSM changes from baseline in EQ-5D-3L utility scores and VAS indicated worsening in both groups (Online Resource Fig. 1). LSM for utility scores differed between groups (difference, -0.07 ; 95% CI -0.13 to -0.01 ; nominal $p=0.029$) but not for VAS (difference -2.37 ; 95% CI -7.17 to 2.43 ; nominal $p=0.331$).

Proportion of patients with deteriorated or improved status at week 12

At week 12, 41% and 33% of patients in the pembrolizumab group and the paclitaxel group, respectively, experienced deterioration from baseline in the EORTC QLQ-C30 GHS/QoL mean score change; 23% in both groups experienced improvement (Fig. 3). Except for fatigue, scores for functioning and symptom subscales showed similar degrees of worsening and improvement. Fatigue symptom subscale scores improved in more and deteriorated in fewer pembrolizumab-treated patients than paclitaxel-treated patients (improved, 28% pembrolizumab and 22% paclitaxel; deteriorated, 36% pembrolizumab and 50% paclitaxel) (Fig. 3).

Time to deterioration

Among the 41% pembrolizumab-treated and 33% of paclitaxel-treated patients who experienced deterioration in GHS/QoL scores, median TTD was 10.1 months in the pembrolizumab group and 6.9 months in the paclitaxel group (HR 1.06; 95% CI 0.71–1.58) (Fig. 4a); the Kaplan–Meier plot revealed a slightly lower curve in the first 3 months in the pembrolizumab group compared with the paclitaxel group. Median TTD was similar for pembrolizumab and paclitaxel for the EORTC QLQ-C30 subscales for nausea/vomiting (HR 0.81; 95% CI 0.50–1.33; 15% of all patients in both groups experienced deterioration) and appetite loss (HR 1.22; 95% CI 0.76–1.96; 36% of pembrolizumab-treated and 27% of paclitaxel-treated patients experienced deterioration) and for EORTC QLQ-STO22 pain (HR 1.09; 95% CI 0.65–1.83; 29% of pembrolizumab-treated and 27% of paclitaxel-treated patients experienced deterioration) (Fig. 4b–d).

Discussion

In this prespecified exploratory analysis, the observed effects in HRQoL were comparable for patients with advanced gastric/GEJ cancer and PD-L1 CPS ≥ 1 regardless of whether they received second-line pembrolizumab monotherapy or paclitaxel. Compliance rates were high in both groups. Both treatment groups showed some worsening of functional and symptom subscale scores at week 12. The LSM of GHS/QoL scores worsened during the first 12 weeks in both treatment groups, with a confidence interval crossing zero for the difference in LSM; the LSM improved in pembrolizumab-treated patients after week 18. TTD was also similar for both groups.

Overall, HRQoL as measured by the GHS/QoL and functional subscales from baseline to week 12 worsened in both groups, with overlapping confidence intervals between the treatment groups for many of the subscale scores (Figs. 1, 2b). Nearly all symptoms measured by the EORTC QLQ-C30 and the EORTC QLQ-STO22 worsened from baseline to week 12 in both treatment groups, with many overlapping confidence intervals between the treatment groups (Fig. 2b, c). Although fatigue and diarrhea subsided in more and grew in fewer pembrolizumab-treated patients than paclitaxel-treated patients, the only symptom showing an apparent difference was hair loss, which, as expected, was worse with paclitaxel than with pembrolizumab. As with GHS/QoL scores, there was no difference in TTD at week 12 between treatment groups in the EORTC QLQ-C30 subscales for nausea/vomiting and appetite loss or in the EORTC QLQ-STO22 scale for pain. However, these results were consistent with the primary safety analysis of all patients (regardless of CPS status) from KEYNOTE-061, in which fewer patients experienced treatment-related AEs in the pembrolizumab group (53% overall, 14% grade 3–5) than in the paclitaxel group (84% and 35%, respectively) [9]. Additionally, we observed a worsening of utility scores in both treatment groups using the descriptive EQ-5D-3L questionnaire.

Interpretation of the observations from this exploratory analysis may be limited by the open-label nature of the trial and the short duration of follow-up attributed to the high rate of discontinuation, usually because of disease progression. As previously discussed in the primary analysis of KEYNOTE-061, we observed crossing of the survival curves in the second-line setting, suggesting that some pembrolizumab-treated patients experienced early disease progression and poor outcomes [9]. However, there was a trend toward better outcomes for pembrolizumab-treated patients who achieved disease control and could be maintained on therapy, as evidenced by the latter part of the survival curve [9]. These findings may be attributed to

Fig. 3 Proportion of patients with deteriorated or improved status in EORTC QLQ-C30 scores at week 12. **a** Pembrolizumab. **b** Paclitaxel. *EORTC* European Organisation for Research and Treatment of Cancer, *GHS*, global health status; *QLQ-30* Quality of Life Questionnaire Core 30, *QLQ-STO22*, health-related QoL questionnaire in gastric cancer; *QoL*, quality of life







Fig. 4 TTD in the **a** EORTC QLQ-C30 GHS/QoL scale, **b** EORTC QLQ-C30 nausea/vomiting subscale, **c** EORTC QLQ-C30 appetite loss subscale, and **d** EORTC QLQ-STO22 pain subscale. *GHS* global health status, *Q3W* every 3 weeks, *QLQ-30* Quality of Life Questionnaire Core 30, *QLQ-STO22* health-related QoL questionnaire in gastric cancer, *QoL* quality of life, *TTD* time to deterioration




No. at risk		0	3	6	9	12	15	18
Pembrolizumab	173	61	32	24	11	9	8	
Paclitaxel	171	62	15	9	4	1	1	



No. at risk		0	3	6	9	12	15	18
Pembrolizumab	173	70	44	27	11	9	8	
Paclitaxel	171	69	20	9	3	1	1	



No. at risk		0	3	6	9	12	15	18
Pembrolizumab	173	65	40	26	11	9	8	
Paclitaxel	171	74	20	5	2	1	1	



No. at risk		0	3	6	9	12	15	18
Pembrolizumab	171	70	42	30	11	9	8	
Paclitaxel	171	73	23	11	4	1	1	

the time it takes to induce an antitumor immune response [9]. As a result, the HRQoL data must be carefully interpreted with these findings in mind. Another limitation of this HRQoL analysis was the week 12 end point because separation between the treatment groups in the GHS/QoL score appeared after that point.

Conclusions

In the KEYNOTE-061 trial comparing pembrolizumab and paclitaxel as second-line treatments for patients with advanced gastric/GEJ cancer and PD-L1 CPS ≥ 1 , the study groups experienced generally similar HRQoL from baseline through 12 weeks. In overall scores and in specific subscales and items, pembrolizumab did not appear to worsen HRQoL to a greater extent than paclitaxel. Even though the HRQoL questionnaires were not intended to evaluate AEs, these results suggest that patient-reported impacts of specific symptoms (e.g., fatigue, hair loss, decreased appetite) were consistent with the safety results of KEYNOTE-061, which showed fewer AEs with pembrolizumab than paclitaxel.

Data sharing

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD) is committed to providing qualified scientific researchers access to anonymized data and clinical study reports from the company's clinical trials for the purpose of conducting legitimate scientific research. MSD is also obligated to protect the rights and privacy of trial participants and, as such, has a procedure in place for evaluating and fulfilling requests for sharing company clinical trial data with qualified external scientific researchers. The MSD data-sharing website (available at: http://engagzone.msd.com/ds_documentation.php) outlines the process and requirements for submitting a data request. Applications will be promptly assessed for completeness and policy compliance. Feasible requests will be reviewed by a committee of MSD subject matter experts to assess the scientific validity of the request and the qualifications of the requestors. In line with data privacy legislation, submitters of approved requests must enter into a standard data-sharing agreement with MSD before data access is granted. Data will be made available for request after product approval in the US and EU or after product development is discontinued. There are circumstances that may prevent MSD from sharing requested data, including country or region-specific regulations. If the request is declined, it will be communicated to the investigator. Access to genetic or exploratory biomarker data requires a detailed, hypothesis-driven statistical analysis plan that is collaboratively developed by the requestor and MSD subject

matter experts; after approval of the statistical analysis plan and execution of a data-sharing agreement, MSD will either perform the proposed analyses and share the results with the requestor or will construct biomarker covariates and add them to a file with clinical data that is uploaded to an analysis portal so that the requestor can perform the proposed analyses.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s10120-021-01200-w>.

Acknowledgements We thank the patients and their families as well as the investigators and site personnel involved in the study. Medical writing and/or editorial assistance was provided by Tim Peoples, MA, ELS, Traci Stuve, MA, and Holly C. Cappelli, PhD, CMPP, of ApotheCom (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Author contributions Conception, design, or planning of the study: EVC, M. Amonkar, CSF, JMN, and KS. Analysis of the data: EVC, MO, HCC, KM, ZAW, and XC. Acquisition of the data: EVC, M. Alsina, MO, YJB, HCC, EG, AB, WS, ZAW, CSS, and KS. Interpretation of the results: EVC, M. Amonkar, CSF, M. Alsina, MO, YJB, HCC, ZAW, JMN, XC, CSS, and KS. Drafting of the manuscript: MO, HCC, and KS. Critically reviewing or revising the manuscript for important intellectual content: all authors. Final approval: all authors.

Funding This study was sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Declarations

Conflict of interest E. Van Cutsem has received research funding (to his institution) from Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Ipsen, Lilly, Merck KGaA, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Novartis, Roche, and Servier. He has also served in an advisory/consultancy role for Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Incyte, Lilly, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Merck KGaA, Novartis, Roche, and Servier. M. Amonkar reports employment at Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and is stockholder of Merck & Co., Inc., Kenilworth, NJ, USA. C. S. Fuchs served in an advisory/consultancy role for Agios, Amylin Pharmaceuticals, Bain Capital, CytomX Therapeutics, Daiichi-Sankyo, Eli Lilly, Entrinsic Health, EvolveImmune Therapeutics, Genentech, Merck, Taiho, and Unum Therapeutics. He also serves as a director for CytomX Therapeutics and owns unexercised stock options for CytomX and Entrinsic Health. He is a cofounder of EvolveImmune Therapeutics and has equity in this private company. M. Alsina has received honoraria from Bristol Myers Squibb, Lilly, MSD, and Servier and served in an advisory/consultancy role for Bristol Myers Squibb, Lilly, MSD, and Servier. M. Özgüroğlu has received honoraria (personal and to his institution) from Astellas, Janssen, Novartis, Roche, and Sanofi; served in an advisory/consultancy role for Astellas, Janssen, and Sanofi; and received travel/accommodations from AstraZeneca, Bristol Myers Squibb, and Janssen. Y.-J. Bang served in an advisory/consultancy role for AstraZeneca, Novartis, Genentech/Roche, MSD, Merck Serono, Bayer, Bristol Myers Squibb, Eli Lilly, Taiho, Daiichi-Sankyo, Astellas, BeiGene, GreenCross, Samyang Biopharm, Hanmi, and Genexine and received research grant/funding (to his institution) from MSD, AstraZeneca, Novartis, Genentech/Roche,

Merck Serono, Bayer, Bristol Myers Squibb, GlaxoSmithKline, Pfizer, Eli Lilly, Boehringer Ingelheim, MacroGenics, Boston Biomedical, FivePrime, Curis, Taiho, Takeda, Ono, Daiichi Sankyo, Astellas, BeiGene, Green Cross, CKD Pharma, and Genexine. H. C. Chung has received honoraria from Merck Serono, Lilly, Foundation Medicine; served in an advisory/consultancy role for Taiho, Celltrion, MSD, Lilly, Quintiles, Bristol Myers Squibb, Merck Serono, Gloria, BeiGene, Amgen, and Zymeworks; and received research grants/funding (to his institution) from Lilly, GlaxoSmithKline, MSD, Merck Serono, Bristol Myers Squibb/Ono, Taiho, Amgen, and BeiGene. K. Muro has received honoraria for speaking from Bristol Myers Squibb, Eli Lilly, Chugai Pharmaceutical, Takeda Pharmaceutical, Taiho Pharmaceutical, Ono Pharmaceutical Co., Ltd., and Sanofi; served in an advisory/consultancy role for AstraZeneca, Amgen, and Ono Pharmaceutical Co., Ltd; and received research funding (to his institution) from MSD, Daiichi Sankyo, Parexel International, Sumitomo Dainippon Pharma, Pfizer, Mediscience Planning, Solasia Pharma, and Sanofi. E. Goekurt has served in an advisory/consultancy role for Bristol Myers Squibb, Lilly, Merck KGaA, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Roche, and Servier. A. Benson has served in an advisory/consultancy role for CN, Bristol Myers Squibb, Patient Resource (educational document review), Research to Practice, AVBCC, Harborside, Therabionic, Guardant, Merck (DMC), Terumo, Lexicon, ACCC, ECOG-ACRIN, Amgen, Imedex, Artemida Pharma, Intellisphere OncLiv, American College of Radiology, China National Medical Association 6th Affiliated Sun Yat-Sen Hospital, Springer, Health Advances, Lexicon, Array (Pfizer), NCCN, and ACCC. W. Sun has received research grant/funding (personal and to his institution) from Merck. Z. A. Wainberg has served in an advisory/consultancy role for AstraZeneca, Bayer, Daiichi, Five Prime, Lilly, Merck, and Molecular Templates; received funding (to his institution) from AstraZeneca, Daiichi, Five Prime, Lilly, and Merck; and received travel/accommodations from Bayer, Daiichi, Lilly, Merck, and Molecular Templates. J. M. Norquist is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and a stockholder in Merck & Co., Inc., Kenilworth, NJ, USA. X. Chen is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and a stockholder in Merck & Co., Inc., Kenilworth, NJ, USA. C.-S. Shih is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and a stockholder in Merck & Co., Inc., Kenilworth, NJ, USA. K. Shitara has received honoraria from AbbVie, Novartis, and Yakult; served in an advisory/consultancy role for Astellas Pharma, Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical, Taiho, MSD, Novartis, AbbVie, GlaxoSmithKline; and received research grants/funding (to his institution) from Lilly, Ono Pharmaceutical, Dainippon Sumitomo Pharma, MSD, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical, Astellas Pharma, and Mediscience.

Human rights statement and informed consent The study was conducted in accordance with the protocol and its amendments and with Good Clinical Practice guidelines.

Informed consent All patients provided written informed consent before enrollment.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not

permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.


References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: Cancer J Clin.* 2018;68:394–424.
2. Casamayor M, Morlock R, Maeda H, Ajani J. Targeted literature review of the global burden of gastric cancer. *Ecancer Med Sci.* 2018;12:883.
3. McKernan M, McMillan DC, Anderson JR, Angerson WJ, Stuart RC. The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesophageal cancer. *Br J Cancer.* 2008;98:888–93.
4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer (Version 4.2020).
5. van Kleef JJ, Ter Veer E, van den Boorn HG, Schokker S, Ngai LL, Prins MJ, et al. Quality of life during palliative systemic therapy for oesophagogastric cancer: systematic review and meta-analysis. *J Natl Cancer Inst.* 2020;112:12–29.
6. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. *Lancet Oncol.* 2016;17:717–26.
7. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. *JAMA Oncol.* 2018;4:e180013.
8. KEYTRUDA® (pembrolizumab) for injection, for intravenous use, 03/2021. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA 2021.
9. Shitara K, Ozguroglu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu M-H, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. *Lancet.* 2018;392:123–33.
10. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst.* 1993;85:365–76.
11. Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S. Test/retest study of the European organization for research and treatment of cancer core quality-of-life questionnaire. *J Clin Oncol.* 1995;13:1249–54.
12. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. *J Clin Oncol.* 1998;16:139–44.
13. Ringdal GI, Ringdal K. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. *Qual Life Res.* 1993;2:129–40.
14. Vickery CW, Blazeby JM, Conroy T, Arraras J, Sezer O, Koller M, et al. Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer. *Eur J Cancer.* 2001;37:966–71.
15. Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. *Eur J Cancer.* 2004;40:2260–8.
16. The EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. *Health Policy.* 1990;16:199–208.

17. The EuroQol Group. EQ-5D-3L: a measure of health-related quality of life. <https://euroqol.org/eq-5d-instruments/eq-5d-3l-about/>. Accessed September 28, 2020.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Eric Van Cutsem¹ · Mayur Amonkar² · Charles S. Fuchs³ · Maria Alsina⁴ · Mustafa Özgüroğlu⁵ · Yung-Jue Bang⁶ · Hyun Cheol Chung⁷ · Kei Muro⁸ · Eray Goekkurt⁹ · Al B. Benson III¹⁰ · Weijing Sun¹¹ · Zev A. Wainberg¹² · Josephine M. Norquist² · Xinqun Chen¹³ · Chie-Schin Shih¹³ · Kohei Shitara¹⁴ 

¹ Department of Digestive Oncology, University Hospitals Gasthuisberg Leuven and KU Leuven, 49 Herestraat, Leuven, Belgium

² Center for Observational and Real World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA

³ Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA

⁴ Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology, University Autònoma de Barcelona, Barcelona, Spain

⁵ Department of Internal Medicine, Medical Oncology, and Clinical Trial Unit, Cerrahpaşa School of Medicine, Istanbul University–Cerrahpaşa, Istanbul, Turkey

⁶ Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea

⁷ Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

⁸ Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

⁹ North-German Trial Center for Innovative Oncology, Hematology Oncology Practice Eppendorf, University Cancer Center Hamburg, Hamburg, Germany

¹⁰ Robert H. Lurie Comprehensive Cancer Center, Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

¹¹ Department of Internal Medicine and Medical Oncology, University of Kansas, Westwood, KS, USA

¹² Department of Medicine and Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

¹³ Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA

¹⁴ Department of Gastrointestinal Oncology, National Cancer Center Hospital, Chiba, Japan